Business
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of an underwritten public offering of 7,175,000 shares of its common stock at a public offering price of $16.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of common stock at
About this update from Bicara Therapeutics Inc.
[{"type":"image","alt":"Bicara Therapeutics Inc.","displaySize":"","headline":null,"caption":"Bicara Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/6ccfcafb8abd88270fbc9bc7dafef0fe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/N7aaUVu45bXz.VUeCxgrhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6ccfcafb8abd88270fbc9bc7dafef0fe","width":300,"height":86}},"lazy":false},{"type":"text","content":"BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of an underwritten public offering of 7,175,000 shares of its common stock at a public offering price of $16.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of common stock at a public offering price of $15.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Bicara from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Bicara, are expected to be approximately $150 million, excluding any exercise of the underwriters’ option to purchase additional shares and excluding the exercise of any pre-funded warrants. All shares and pre-funded warrants in the offering are being sold by Bicara. The offering is expected to close on or about February 26, 2026, subject to the satisfaction of customary closing conditions. In addition, Bicara has granted the underwriters a 30-day option to purchase up to 1,406,250 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.","length":1446,"tagName":"p"},{"type":"text","content":"Bicara intends to use the net proceeds of the offering to further invest in and build its medical and commercial infrastructure to support a planned regulatory filing and commercial launch for ficerafusp alfa, if approved, in the U.S.; to further accelerate the development of ficerafusp alfa in 1L R/M HPV-negative HNSCC, includ...